China has huge diabetic population now. That's why they offered $50m for an investment in Oramed. With approved drug, MNKD should get much larger deal than what Oramed got.
Remember Dr. Kim said dMab is manufactured by the body after injection, which is definitely better than mAb manufactured outside of body and injected with large quantity.
What's the next company for sale on BB's top 10 list?
with 20% stocks on short, it will be interesting to see what action shorts will take.
If MNKD can sell 150M shares to some big investors or a potential partner, it will be a big boost to its share price. With the potential of Afrezza, dilution is not an issue. It will put the concern about BK away.
Matt said Sanofi primarily targeted T2 patients, which was totally wrong. It should start with T1 patients as T1 patients already familiar with insulin usage, and many have CGM. It's much easier to T1 to master the usage of Afrezza and see the advantage.
New article on Marketwatch.
It didn't mention which company's hTERT vaccine is used. Guess?
This could be Al's idea to create diabetic care center with new treatment protocol.